NVTR News and Press, Nuvectra Corporation From 10/31/18

PLANO, Texas, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to participate i...

Quick Take The Axonics Modulation ( AXNX ) IPO is indicating significant demand according to IPO information service IPO Boutique. Axonics sells a sacral neuromodulation system for the treatment of several urinary conditions. Although life science firms may be somewhat less affected by s...

Nuvectra Corporation (NVTR) Q3 2018 Earnings Conference Call October 29, 2018 4:30 P.M. ET Executives Tram Bui - The Ruth Group Scott Drees - Chief Executive Officer Walter Berger - Chief Operating Officer and Chief Financial Officer Analysts Matthew O'Brien - Piper Jaffray...

Nuvectra Corporation (NASDAQ: NVTR ): Q3 GAAP EPS of -$0.87 beats by $0.04 . More news on: Nuvectra Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

Reports Record Algovita ® Sales of $12.5 million, Up 98% YoY PLANO, Texas, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the third quarter ended September 30, 2018. Hig...

Quick Take Axonics Modulation Technologies ( AXNX ) intends to raise $100 million from the sale of its common stock in an IPO, per an amended registration statement . The company is developing a sacral neuromodulation device to treat a number of urinary tract conditions. AXNX is neari...

PLANO, Texas, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the third quarter ended September 30, 2018 on Monday, October 29, 2018 after market close. Nuvectr...

Quick Take Axonics Modulation Technologies ( AXNX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm develops and commercializes minimally invasive sacral neuromodulation (SNM) solutions. AXNX hopes to raise publi...